Sigma-Aldrich enhances API services with purchase of Pharmorphix
Sigma-Aldrich Corporation has acquired Pharmorphix, a privately-owned company in Cambridge, UK that offers solid-form research services to the global pharmaceutical and biotech markets.
Sigma-Aldrich Corporation has acquired Pharmorphix, a privately-owned company in Cambridge, UK that offers solid-form research services to the global pharmaceutical and biotech markets.
The global life sciences supplier said Pharmorphix would increase the customer base of its custom manufacturing division, SAFC Pharma, as well as enhancing its technology services offering.
Operating from the Cambridge Science Park, Pharmorphix had sales of around US$5m over the past 12 months. Its services are sold to a large number of pharmaceutical and biotech customers that require information on the solid state of therapeutics to support regulatory and intellectual property submissions.
SAFC's president, Frank Wicks, said: "Recently-published FDA guidelines concerning specification of API solid form make the services provided by firms such as Pharmorphix crucial to the pharmaceutical industry. In addition, better understanding and characterisation of solid form provides valuable intellectual property that can be used to extend the patent life of new therapeutics."
The current Pharmorphix management team will remain with the company. Terms of the purchase, which were not disclosed, were paid in cash.
